HRTX Key Statistics, Chart & Performance
The current stock price of HRTX is 1.31 USD. In the past month the price increased by 19.09%. In the past year, price decreased by -19.14%.
HRTX Latest News, Press Relases and Analysis
HRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About HRTX
Company Profile
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 122 full-time employees. The company creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Company Info
HERON THERAPEUTICS INC
100 Regency Forest Drive, Suite 300
Cary NORTH CAROLINA 92121 US
CEO: Barry Quart
Employees: 122
Phone: 18582514400
HERON THERAPEUTICS INC / HRTX FAQ
What does HERON THERAPEUTICS INC do?
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 122 full-time employees. The company creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Can you provide the latest stock price for HERON THERAPEUTICS INC?
The current stock price of HRTX is 1.31 USD.
Does HRTX stock pay dividends?
HRTX does not pay a dividend.
How is the ChartMill rating for HERON THERAPEUTICS INC?
HRTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for HERON THERAPEUTICS INC?
HERON THERAPEUTICS INC (HRTX) currently has 122 employees.
Can you provide the market cap for HERON THERAPEUTICS INC?
HERON THERAPEUTICS INC (HRTX) has a market capitalization of 240.20M USD. This makes HRTX a Micro Cap stock.
Who owns HERON THERAPEUTICS INC?
You can find the ownership structure of HERON THERAPEUTICS INC (HRTX) on the Ownership tab.
HRTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HRTX. When comparing the yearly performance of all stocks, HRTX is a bad performer in the overall market: 75.68% of all stocks are doing better.
HRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HRTX. There are concerns on the financial health of HRTX while its profitability can be described as average.
HRTX Financial Highlights
Over the last trailing twelve months HRTX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 83.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.45% | ||
| ROE | -91.22% | ||
| Debt/Equity | 2.16 |
HRTX Forecast & Estimates
10 analysts have analysed HRTX and the average price target is 4.59 USD. This implies a price increase of 250.38% is expected in the next year compared to the current price of 1.31.
For the next year, analysts expect an EPS growth of 22.37% and a revenue growth 9.43% for HRTX